Vitamin D and Hepatitis C Virus-relatedLiver Disease

Document Type : Original Article

Authors

1 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.

2 Debartment of Biochemistry, Faculty of Medicine, Sohag University.

3 Department of Medical Microbiology and Immunology,Faculty of Medicine, Sohag University.

Abstract

Vitamin D through the vitamin D receptor (VDR) is involved in the control of bone and calcium homeostasis, immunoregulation, cellular differentiation,and anti-inflammatoryactions.The liver is central in vitamin D synthesis, however the direct involvement ofthe vitamin D with chronic liver disease, chronic hepatitis C (CHC) infection, and hepatocellular carcinoma (HCC) remains to be evaluated.The purpose of thisreview is to describevitamin D metabolism, the mechanisms of homeostatic control, and to address the associationsbetween vitamin D and HCV-related liver disease.

References

  1. Combs GF, McClung JP. Vitamin D. In: Combs GF, McClung JP (Eds.), The Vitamins, Fundamental Aspects in Nutrition and Health, 5th ed. London: Academic Press, 2017; 161–206.
  2. Holick MF. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical application. In: Favus MJ (Ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd Edition. Philadelphia: Lippincott-Raven, 1996; 74–81.
  3. Lehmann B, MeurerM.Vitamin D metabolism.DermatolTher 2010; 23: 2–12.
  4. Kamao M, Tatematsu S, Hatakeyama S, et al. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 2004; 279: 15897–15907.
  5. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch BiochemBiophys 2012; 523: 9–18.
  6. Dusso AS, Brown AJ, Slatopolsky E.Vitamin D.Am J Physiol Renal Physiol 2005; 289: F8–28.
  7. Norman AW, Okamura WH, Hammond MW, et al. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1alpha,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-scis-nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol 1997; 11: 1518–1531.
  8. Gil Á, Plaza-Diaz J, Mesa MD.Vitamin D: Classic and Novel Actions.Ann NutrMetab 2018; 72: 87–95.
  9. Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96: 365–408.
  10. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252–261.
  11. Ma Y, Johnson CS, Trump DL. Mechanistic insights of vitamin D anticancer effects. VitamHorm 2016; 100: 395–431.
  12. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634–1647.
  13. Bikle D.Nonclassic actions of vitamin D.J ClinEndocrinolMetab 2009; 94: 26–34.
  14. BoonstraA, Barrat FJ, Crain C, et al. 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980.
  15. Penna G, AdoriniL. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411.
  16. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067–1077.
  17. Kitson MT, Roberts SK.D-livering the message: the importance of vitamin D status in chronic liver disease.J Hepatol 2012; 57: 897–909.
  18. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624–2628.
  19. Reese PP, Bloom RD, Feldman HI, et al.Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation.Liver Int 2012; 32: 287–296.
  20. Malham M, Jørgensen SP, Ott P, et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than Aetiology. World J Gastroenterol 2011; 17: 922–925.
  21. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. ClinGastroenterolHepatol 2007; 5: 513–520.
  22. Stokes CS, Volmer DA, Grünhage F, et al.Vitamin D in chronic liver disease.Liver Int 2013; 33: 338–352.
  23. BlachS, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet GastroenterolHepatol 2017; 2: 161–176.
  24. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev GastroenterolHepatol 2013; 10: 553–562.
  25. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887–893.
  26. Gal-TanamyM, Bachmetov L, Ravid A, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570–1579.
  27. BitettoD, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118–1126.
  28. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV–HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756–761.
  29. Baur K, Mertens JC, Schmitt J, et al.Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients.Liver Int 2012; 32: 635–643.
  30. Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018; 68: 394–424.
  31. Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. AbdomRadiol 2018; 43: 13–25.
  32. Flanagan JN, Zheng S, Chiang KC, et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009; 29: 3547–3553.
  33. PourgholamiMH, Akhter J, Lu Y, et al. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 2000; 151: 97–102.
  34. Caputo A, Pourgholami MH, Akhter J, et al. 1,25-Dihydroxyvitamin D3 induced cell cycle arrest in the human primary liver cancer cell line HepG2. Hepatol. Res 2003; 26: 34–39.
  35. Chiang KC, Yeh CN, Chen MF, et al.Hepatocellular carcinoma and vitamin D: a review.J GastroenterolHepatol 2011; 26: 1597–1603.
  36. Bandera-Merchan B, Morcillo S, Martin-Nuñez G, et al. The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences. J Steroid BiochemMolBiol 2017; 167: 203–218.
  37. VuoloL, Di Somma C, Faggiano A, et al.Vitamin D and cancer.Front Endocrinol 2012; 3: 58.

 

 

Sohag Medical Journal
Volume 23, Issue 1
January 2019
Pages 31-38

Files

Share

How to cite

Statistics